{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:22:23Z","timestamp":1763018543483,"version":"build-2065373602"},"reference-count":185,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.smim.2022.101633","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T21:25:59Z","timestamp":1656710759000},"page":"101633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Emerging opportunities for C3 inhibition in the eye"],"prefix":"10.1016","volume":"59","author":[{"given":"Benjamin J.","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios C.","family":"Mastellos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Lambris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.smim.2022.101633_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/imr.12500","article-title":"Complement component C3 - The \u201cSwiss Army Knife\u201d of innate immunity and host defense","volume":"274","author":"Ricklin","year":"2016","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.smim.2022.101633_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.it.2017.03.003","article-title":"Complement C3-targeted therapy: replacing long-held assertions with evidence-based discovery","volume":"38","author":"Mastellos","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.smim.2022.101633_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100936","article-title":"Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions","volume":"83","author":"Kim","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.smim.2022.101633_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.04.002","article-title":"Immune privilege in corneal transplantation","volume":"72","author":"Hori","year":"2019","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.smim.2022.101633_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.preteyeres.2018.10.003","article-title":"Immune regulation in the aging retina","volume":"69","author":"Chen","year":"2019","journal-title":"Prog. Retin Eye Res"},{"issue":"6","key":"10.1016\/j.smim.2022.101633_bib6","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","article-title":"Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study","volume":"113","author":"Jaffe","year":"2006","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.smim.2022.101633_bib7","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"issue":"21","key":"10.1016\/j.smim.2022.101633_bib8","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.smim.2022.101633_bib9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41591-018-0295-0","article-title":"Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect","volume":"25","author":"Cideciyan","year":"2019","journal-title":"Nat. Med"},{"key":"10.1016\/j.smim.2022.101633_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.100827","article-title":"Progress in treating inherited retinal diseases: Early subretinal gene therapy clinical trials and candidates for future initiatives","volume":"77","author":"Garafalo","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.smim.2022.101633_bib11","article-title":"Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration","author":"Holekamp","year":"2021","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.smim.2022.101633_bib12","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.smim.2022.101633_bib13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"Del Amo","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"issue":"5720","key":"10.1016\/j.smim.2022.101633_bib14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1126\/science.1110189","article-title":"Complement factor H polymorphism and age-related macular degeneration","volume":"308","author":"Edwards","year":"2005","journal-title":"Science"},{"issue":"20","key":"10.1016\/j.smim.2022.101633_bib15","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.1073\/pnas.0501536102","article-title":"A common haplotype in the complement regulatory gene factor H (HF1\/CFH) predisposes individuals to age-related macular degeneration","volume":"102","author":"Hageman","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5720","key":"10.1016\/j.smim.2022.101633_bib16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1126\/science.1110359","article-title":"Complement factor H variant increases the risk of age-related macular degeneration","volume":"308","author":"Haines","year":"2005","journal-title":"Science"},{"issue":"5720","key":"10.1016\/j.smim.2022.101633_bib17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/science.1109557","article-title":"Complement factor H polymorphism in age-related macular degeneration","volume":"308","author":"Klein","year":"2005","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.smim.2022.101633_bib18","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1016\/j.celrep.2019.10.084","article-title":"Cell-type-specific complement expression in the healthy and diseased retina","volume":"29","author":"Pauly","year":"2019","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.smim.2022.101633_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.preteyeres.2009.11.003","article-title":"The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited","volume":"29","author":"Anderson","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"issue":"6","key":"10.1016\/j.smim.2022.101633_bib20","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","article-title":"The classical complement cascade mediates CNS synapse elimination","volume":"131","author":"Stevens","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.smim.2022.101633_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fnagi.2018.00015","article-title":"The complement system is critical in maintaining retinal integrity during aging","volume":"10","author":"Mukai","year":"2018","journal-title":"Front Aging Neurosci."},{"issue":"2","key":"10.1016\/j.smim.2022.101633_bib22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ajpath.2013.04.008","article-title":"Complement component C3 plays a critical role in protecting the aging retina in a murine model of age-related macular degeneration","volume":"183","author":"Hoh Kam","year":"2013","journal-title":"Am. J. Pathol."},{"issue":"12","key":"10.1016\/j.smim.2022.101633_bib23","doi-asserted-by":"crossref","first-page":"7684","DOI":"10.1167\/iovs.12-10069","article-title":"A novel role of complement in retinal degeneration","volume":"53","author":"Yu","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.smim.2022.101633_bib24","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1038\/s41467-019-12780-8","article-title":"Single-cell transcriptomic atlas of the human retina identifies cell types associated with age-related macular degeneration","volume":"10","author":"Menon","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2022.101633_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108391","article-title":"Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates","volume":"214","author":"Hughes","year":"2020","journal-title":"Clin. Immunol."},{"issue":"7","key":"10.1016\/j.smim.2022.101633_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1167\/iovs.62.7.26","article-title":"Differential and altered spatial distribution of complement expression in age-related macular degeneration","volume":"62","author":"Demirs","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.smim.2022.101633_bib27","first-page":"38","article-title":"Activation of the lectin pathway of complement in experimental human keratitis with Pseudomonas aeruginosa","volume":"20","author":"Osthoff","year":"2014","journal-title":"Mol. Vis."},{"issue":"11","key":"10.1016\/j.smim.2022.101633_bib28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/02713680701656343","article-title":"Complement deposits on ocular tissues adjacent to sites of inflammation","volume":"32","author":"Montalvo","year":"2007","journal-title":"Curr. Eye Res."},{"issue":"9","key":"10.1016\/j.smim.2022.101633_bib29","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/gb-2005-6-9-r74","article-title":"Differential gene expression in anatomical compartments of the human eye","volume":"6","author":"Diehn","year":"2005","journal-title":"Genome Biol."},{"issue":"3","key":"10.1016\/j.smim.2022.101633_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/omi.2019.0190","article-title":"What makes cornea immunologically unique and privileged? Mechanistic clues from a high-resolution proteomic landscape of the human cornea","volume":"24","author":"Subbannayya","year":"2020","journal-title":"OMICS"},{"issue":"2","key":"10.1016\/j.smim.2022.101633_bib31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nm814","article-title":"Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells","volume":"9","author":"Sohn","year":"2003","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.smim.2022.101633_bib32","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.immuni.2013.10.018","article-title":"Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation","volume":"39","author":"Liszewski","year":"2013","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.smim.2022.101633_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/imr.12474","article-title":"Evolution of the complement system: from defense of the single cell to guardian of the intravascular space","volume":"274","author":"Elvington","year":"2016","journal-title":"Immunol. Rev."},{"issue":"36","key":"10.1016\/j.smim.2022.101633_bib34","doi-asserted-by":"crossref","first-page":"9014","DOI":"10.1073\/pnas.1805039115","article-title":"Aberrant early endosome biogenesis mediates complement activation in the retinal pigment epithelium in models of macular degeneration","volume":"115","author":"Kaur","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.smim.2022.101633_bib35","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ophtha.2013.01.004","article-title":"Age-related macular degeneration and modification of systemic complement factor H production through liver transplantation","volume":"120","author":"Khandhadia","year":"2013","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.smim.2022.101633_bib36","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1167\/iovs.14-15910","article-title":"Local production of the alternative pathway component factor B is sufficient to promote laser-induced choroidal neovascularization","volume":"56","author":"Schnabolk","year":"2015","journal-title":"Invest Ophthalmol. Vis. Sci."},{"issue":"7","key":"10.1016\/j.smim.2022.101633_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/32b9bc31-ed6d-4d31-9ce0-480407017bad","article-title":"Systemic complement activation in age-related macular degeneration","volume":"3","author":"Scholl","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.smim.2022.101633_bib38","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.3389\/fimmu.2017.01778","article-title":"Bruch\u2019s membrane compartmentalizes complement regulation in the eye with implications for therapeutic design in age-related macular degeneration","volume":"8","author":"Clark","year":"2017","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.smim.2022.101633_bib39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1167\/iovs.61.6.18","article-title":"Rare genetic variants in complement factor I lead to low FI plasma levels resulting in increased risk of age-related macular degeneration","volume":"61","author":"Hallam","year":"2020","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.smim.2022.101633_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.05.026","article-title":"Increased serum proteins in non-exudative AMD retinas","volume":"186","author":"Schultz","year":"2019","journal-title":"Exp. Eye Res."},{"issue":"4","key":"10.1016\/j.smim.2022.101633_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093343","article-title":"Synthesis and propagation of complement C3 by microglia\/monocytes in the aging retina","volume":"9","author":"Rutar","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.smim.2022.101633_bib42","first-page":"e144","volume":"9","author":"Blindness","year":"2021","journal-title":"Glob. Health"},{"issue":"10153","key":"10.1016\/j.smim.2022.101633_bib43","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.smim.2022.101633_bib44","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1096\/fasebj.14.7.835","article-title":"Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease","volume":"14","author":"Mullins","year":"2000","journal-title":"FASEB J."},{"issue":"7","key":"10.1016\/j.smim.2022.101633_bib45","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1073\/pnas.0408835103","article-title":"Drusen complement components C3a and C5a promote choroidal neovascularization","volume":"103","author":"Nozaki","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.smim.2022.101633_bib46","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.smim.2022.101633_bib47","first-page":"182","article-title":"The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity","volume":"36","author":"Klein","year":"1995","journal-title":"Invest Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.smim.2022.101633_bib48","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ophtha.2013.11.023","article-title":"Geographic atrophy: clinical features and potential therapeutic approaches","volume":"121","author":"Holz","year":"2014","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.smim.2022.101633_bib49","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaophthalmol.2014.1019","article-title":"Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials","volume":"132","author":"Ying","year":"2014","journal-title":"JAMA Ophthalmol."},{"issue":"11","key":"10.1016\/j.smim.2022.101633_bib50","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1001\/archopht.123.11.1484","article-title":"The age-related eye disease study severity scale for age-related macular degeneration: AREDS Report No. 17","volume":"123","author":"Davis","year":"2005","journal-title":"Arch. Ophthalmol."},{"issue":"Pt 5","key":"10.1016\/j.smim.2022.101633_bib51","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/eye.1988.106","article-title":"Evolution of geographic atrophy of the retinal pigment epithelium","volume":"2","author":"Sarks","year":"1988","journal-title":"Eye"},{"issue":"5","key":"10.1016\/j.smim.2022.101633_bib52","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S0161-6420(99)00509-6","article-title":"The development of choroidal neovascularization in eyes with the geographic atrophy form of age-related macular degeneration","volume":"106","author":"Sunness","year":"1999","journal-title":"Ophthalmology"},{"issue":"20","key":"10.1016\/j.smim.2022.101633_bib53","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Group","year":"2011","journal-title":"New Engl. J. Med."},{"issue":"12","key":"10.1016\/j.smim.2022.101633_bib54","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.smim.2022.101633_bib55","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ophtha.2018.01.004","article-title":"Development and course of scars in the comparison of age-related macular degeneration treatments trials","volume":"125","author":"Daniel","year":"2018","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.smim.2022.101633_bib56","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/IAE.0000000000001392","article-title":"The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target","volume":"37","author":"Boyer","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.smim.2022.101633_bib57","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.preteyeres.2017.09.001","article-title":"Complement factor H in AMD: bridging genetic associations and pathobiology","volume":"62","author":"Toomey","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"issue":"3","key":"10.1016\/j.smim.2022.101633_bib58","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ophtha.2009.08.032","article-title":"The complement component 5 gene and age-related macular degeneration","volume":"117","author":"Baas","year":"2010","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.smim.2022.101633_bib59","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/ng2131","article-title":"Variation in complement factor 3 is associated with risk of age-related macular degeneration","volume":"39","author":"Maller","year":"2007","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.smim.2022.101633_bib60","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJMoa072618","article-title":"Complement C3 variant and the risk of age-related macular degeneration","volume":"357","author":"Yates","year":"2007","journal-title":"New Engl. J. Med."},{"issue":"11","key":"10.1016\/j.smim.2022.101633_bib61","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/ng.2741","article-title":"Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration","volume":"45","author":"Seddon","year":"2013","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.smim.2022.101633_bib62","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/ng.2758","article-title":"Identification of a rare coding variant in complement 3 associated with age-related macular degeneration","volume":"45","author":"Zhan","year":"2013","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.smim.2022.101633_bib63","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/ng.2740","article-title":"A rare nonsynonymous sequence variant in C3 is associated with high risk of age-related macular degeneration","volume":"45","author":"Helgason","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.smim.2022.101633_bib64","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.preteyeres.2017.03.002","article-title":"The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD","volume":"60","author":"Datta","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"issue":"3","key":"10.1016\/j.smim.2022.101633_bib65","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.survophthal.2020.09.002","article-title":"Oxidative stress as a therapeutic target for the prevention and treatment of early age-related macular degeneration","volume":"66","author":"Jabbehdari","year":"2021","journal-title":"Surv. Ophthalmol."},{"issue":"21","key":"10.1016\/j.smim.2022.101633_bib66","doi-asserted-by":"crossref","first-page":"14534","DOI":"10.1074\/jbc.M114.564674","article-title":"Smoke exposure causes endoplasmic reticulum stress and lipid accumulation in retinal pigment epithelium through oxidative stress and complement activation","volume":"289","author":"Kunchithapautham","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.smim.2022.101633_bib67","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.freeradbiomed.2014.01.015","article-title":"Nrf2 signaling modulates cigarette smoke-induced complement activation in retinal pigmented epithelial cells","volume":"70","author":"Wang","year":"2014","journal-title":"Free Radic. Biol. Med."},{"issue":"11","key":"10.1016\/j.smim.2022.101633_bib68","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1167\/iovs.06-0568","article-title":"Iron induced oxidative damage as a potential factor in age-related macular degeneration: the Cogan Lecture","volume":"47","author":"Dunaief","year":"2006","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"11","key":"10.1016\/j.smim.2022.101633_bib69","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13490","article-title":"Intraocular iron injection induces oxidative stress followed by elements of geographic atrophy and sympathetic ophthalmia","volume":"20","author":"Liu","year":"2021","journal-title":"Aging Cell"},{"issue":"19","key":"10.1016\/j.smim.2022.101633_bib70","doi-asserted-by":"crossref","first-page":"11918","DOI":"10.1074\/jbc.M115.645903","article-title":"Iron-induced local complement component 3 (C3) Up-regulation via Non-canonical transforming growth factor (TGF)-beta signaling in the retinal pigment epithelium","volume":"290","author":"Li","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.smim.2022.101633_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10081170","article-title":"Mitochondrial dysfunction and endoplasmic reticulum stress in age related macular degeneration, role in pathophysiology, and possible new therapeutic strategies","volume":"10","author":"Bilbao-Malave","year":"2021","journal-title":"Antioxidants"},{"issue":"1","key":"10.1016\/j.smim.2022.101633_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054339","article-title":"Mitochondrial DNA variants mediate energy production and expression levels for CFH, C3 and EFEMP1 genes: implications for age-related macular degeneration","volume":"8","author":"Kenney","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.smim.2022.101633_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067894","article-title":"Alternative complement pathway deficiency ameliorates chronic smoke-induced functional and morphological ocular injury","volume":"8","author":"Woodell","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.smim.2022.101633_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.769242","article-title":"Complement factor H-related 3 enhanced inflammation and complement activation in human RPE cells","volume":"12","author":"Schafer","year":"2021","journal-title":"Front Immunol."},{"issue":"12","key":"10.1016\/j.smim.2022.101633_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10121944","article-title":"mTOR inhibition via rapamycin treatment partially reverts the deficit in energy metabolism caused by FH Loss in RPE cells","volume":"10","author":"Merle","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.smim.2022.101633_bib76","first-page":"210","article-title":"Complement C5a receptor knockout has diminished light-induced microglia\/macrophage retinal migration","volume":"23","author":"Song","year":"2017","journal-title":"Mol. Vis."},{"issue":"17","key":"10.1016\/j.smim.2022.101633_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179218","article-title":"Sodium iodate-induced degeneration results in local complement changes and inflammatory processes in murine retina","volume":"22","author":"Enzbrenner","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.smim.2022.101633_bib78","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.4103\/1673-5374.147927","article-title":"Sodium iodate induced retinal degeneration: new insights from an old model","volume":"9","author":"Kannan","year":"2014","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.smim.2022.101633_bib79","article-title":"Myeloid cells in retinal and brain degeneration","author":"Guo","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.smim.2022.101633_bib80","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.preteyeres.2014.11.004","article-title":"Retinal microglia: just bystander or target for therapy?","volume":"45","author":"Karlstetter","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"issue":"4","key":"10.1016\/j.smim.2022.101633_bib81","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrn3710","article-title":"Microglial phagocytosis of live neurons","volume":"15","author":"Brown","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"issue":"9","key":"10.1016\/j.smim.2022.101633_bib82","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.15252\/emmm.201505298","article-title":"Microglial phagocytosis of living photoreceptors contributes to inherited retinal degeneration","volume":"7","author":"Zhao","year":"2015","journal-title":"EMBO Mol. Med."},{"issue":"8","key":"10.1016\/j.smim.2022.101633_bib83","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1084\/jem.20190009","article-title":"C3- and CR3-dependent microglial clearance protects photoreceptors in retinitis pigmentosa","volume":"216","author":"Silverman","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2022.101633_bib84","first-page":"679","article-title":"Ablation of C3 modulates macrophage reactivity in the outer retina during photo-oxidative damage","volume":"26","author":"Jiao","year":"2020","journal-title":"Mol. Vis."},{"issue":"11","key":"10.1016\/j.smim.2022.101633_bib85","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.4161\/auto.36184","article-title":"Dysregulated autophagy in the RPE is associated with increased susceptibility to oxidative stress and AMD","volume":"10","author":"Mitter","year":"2014","journal-title":"Autophagy"},{"issue":"12","key":"10.1016\/j.smim.2022.101633_bib86","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/sctm.20-0211","article-title":"Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of age-related macular degeneration by restoring lysosomal function","volume":"9","author":"Cerniauskas","year":"2020","journal-title":"Stem Cells Transl. Med."},{"issue":"19","key":"10.1016\/j.smim.2022.101633_bib87","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1093\/hmg\/ddv287","article-title":"A local complement response by RPE causes early-stage macular degeneration","volume":"24","author":"Fernandez-Godino","year":"2015","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.smim.2022.101633_bib88","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-3-319-17121-0_8","article-title":"Extracellular matrix alterations and deposit formation in AMD","volume":"854","author":"Fernandez-Godino","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"10.1016\/j.smim.2022.101633_bib89","doi-asserted-by":"crossref","first-page":"9679","DOI":"10.1038\/s41598-018-28143-0","article-title":"C3a triggers formation of sub-retinal pigment epithelium deposits via the ubiquitin proteasome pathway","volume":"8","author":"Fernandez-Godino","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.smim.2022.101633_bib90","doi-asserted-by":"crossref","first-page":"10416","DOI":"10.1038\/s41598-021-89978-8","article-title":"Complement C5 is not critical for the formation of sub-RPE deposits in Efemp1 mutant mice","volume":"11","author":"Garland","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.smim.2022.101633_bib91","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/hmg\/ddt395","article-title":"Mouse genetics and proteomic analyses demonstrate a critical role for complement in a model of DHRD\/ML, an inherited macular degeneration","volume":"23","author":"Garland","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.smim.2022.101633_bib92","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-4419-5635-4_9","article-title":"Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration","volume":"703","author":"Chi","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"issue":"3","key":"10.1016\/j.smim.2022.101633_bib93","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00417-020-04910-6","article-title":"Association of imaging biomarkers and local activation of complement in aqueous humor of patients with early forms of age-related macular degeneration","volume":"259","author":"Sitnilska","year":"2021","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"3","key":"10.1016\/j.smim.2022.101633_bib94","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","article-title":"The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation","volume":"138","author":"Harboe","year":"2004","journal-title":"Clin. Exp. Immunol."},{"issue":"2\u20133","key":"10.1016\/j.smim.2022.101633_bib95","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.molimm.2009.09.005","article-title":"The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification","volume":"47","author":"Harboe","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.smim.2022.101633_bib96","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial","author":"Liao","year":"2019","journal-title":"Ophthalmology"},{"issue":"15","key":"10.1016\/j.smim.2022.101633_bib97","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1021\/jm0603419","article-title":"Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin","volume":"49","author":"Katragadda","year":"2006","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.smim.2022.101633_bib98","first-page":"496","article-title":"First approval of a complement C3 inhibitor opens up autoimmune and inflammatory opportunities","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.smim.2022.101633_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108785","article-title":"From discovery to approval: a brief history of the compstatin family of complement C3 inhibitors","volume":"235","author":"Mastellos","year":"2022","journal-title":"Clin. Immunol."},{"issue":"9","key":"10.1016\/j.smim.2022.101633_bib100","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.ophtha.2021.02.025","article-title":"Characterizing new-onset exudation in the randomized phase 2 FILLY trial of complement inhibitor pegcetacoplan for geographic atrophy","volume":"128","author":"Wykoff","year":"2021","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.smim.2022.101633_bib101","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.smim.2022.101633_bib102","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.oret.2018.10.012","article-title":"Predictive value of the OCT double-layer sign for identifying subclinical neovascularization in age-related macular degeneration","volume":"3","author":"Shi","year":"2019","journal-title":"Ophthalmol. Retin."},{"issue":"5","key":"10.1016\/j.smim.2022.101633_bib103","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ophtha.2019.11.007","article-title":"Structural OCT signs suggestive of subclinical nonexudative macular neovascularization in eyes with large drusen","volume":"127","author":"Narita","year":"2020","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.smim.2022.101633_bib104","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ajo.2010.02.019","article-title":"Retinal pseudocysts in age-related geographic atrophy","volume":"150","author":"Cohen","year":"2010","journal-title":"Am. J. Ophthalmol."},{"issue":"10","key":"10.1016\/j.smim.2022.101633_bib105","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/bjophthalmol-2020-317326","article-title":"Non-neovascular age-related macular degeneration with subretinal fluid","volume":"105","author":"Hilely","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.smim.2022.101633_bib106","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40942-015-0015-6","article-title":"Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration","volume":"1","author":"Dhrami-Gavazi","year":"2015","journal-title":"Int. J. Retin. Vitr."},{"key":"10.1016\/j.smim.2022.101633_bib107","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ajo.2017.07.009","article-title":"Treatment-naive quiescent choroidal neovascularization in geographic atrophy secondary to nonexudative age-related macular degeneration","volume":"182","author":"Capuano","year":"2017","journal-title":"Am. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.smim.2022.101633_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217805","article-title":"Progression of subclinical choroidal neovascularization in age-related macular degeneration","volume":"14","author":"Heiferman","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.smim.2022.101633_bib109","unstructured":"Apellis Pharmaceuticals, Efficacy of intravitreal pegcetacoplan in geographic atrophy. https:\/\/investors.apellis.com\/static-files\/fe6d8c27-e1b2\u20134c87-b77f-aa5cb249bacf, 2022 (accessed 12 February 2022)."},{"issue":"2","key":"10.1016\/j.smim.2022.101633_bib110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ophtha.2015.09.036","article-title":"Natural history of geographic atrophy progression secondary to age-related macular degeneration (Geographic Atrophy Progression Study)","volume":"123","author":"Schmitz-Valckenberg","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.smim.2022.101633_bib111","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2021.02.031","article-title":"Impact of baseline characteristics on geographic atrophy progression in the FILLY trial evaluating the complement C3 inhibitor pegcetacoplan","volume":"227","author":"Steinle","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.smim.2022.101633_bib112","unstructured":"Apellis Pharmaceuticals, Safety of intravitreal pegcetacoplan in geographic atrophy. \u3008https:\/\/investors.apellis.com\/static-files\/8bc6d06d-d1c4\u20134108-9f0d-a5e0939e749b\u3009, 2022 (accessed 12 February 2022)."},{"issue":"9","key":"10.1016\/j.smim.2022.101633_bib113","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41573-019-0031-6","article-title":"Clinical promise of next-generation complement therapeutics","volume":"18","author":"Mastellos","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.smim.2022.101633_bib114","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.smim.2022.101633_bib115","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddac060","article-title":"Rare complement factor I variants associated with reduced macular thickness and age-related macular degeneration in the UK biobank","author":"Tzoumas","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.smim.2022.101633_bib116","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2021.6067","article-title":"Association of pegcetacoplan with progression of incomplete retinal pigment epithelium and outer retinal atrophy in age-related macular degeneration: a post Hoc analysis of the FILLY randomized clinical trial","author":"Nittala","year":"2022","journal-title":"JAMA Ophthalmol."},{"issue":"6","key":"10.1016\/j.smim.2022.101633_bib117","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000510887","article-title":"Can the onset of atrophic age-related macular degeneration be an acceptable endpoint for preventative trials?","volume":"243","author":"Wu","year":"2020","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.smim.2022.101633_bib118","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2021.6068","article-title":"Complement inhibition in age-related macular degeneration-treat early!","author":"Scholl","year":"2022","journal-title":"JAMA Ophthalmol."},{"issue":"40","key":"10.1016\/j.smim.2022.101633_bib119","doi-asserted-by":"crossref","first-page":"29241","DOI":"10.1074\/jbc.M704587200","article-title":"Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition","volume":"282","author":"Janssen","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.smim.2022.101633_bib120","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/eci.12419","article-title":"Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention","volume":"45","author":"Mastellos","year":"2015","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.smim.2022.101633_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2022.01.004","article-title":"Compstatins: the dawn of clinical C3-targeted complement inhibition","author":"Lamers","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"issue":"14","key":"10.1016\/j.smim.2022.101633_bib122","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1021\/acs.jmedchem.8b00560","article-title":"New analogs of the complement C3 inhibitor compstatin with increased solubility and improved pharmacokinetic profile","volume":"61","author":"Berger","year":"2018","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.smim.2022.101633_bib123","doi-asserted-by":"crossref","first-page":"6628","DOI":"10.1167\/iovs.12-9587","article-title":"Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration","volume":"53","author":"Loyet","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.smim.2022.101633_bib124","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/biot.200900218","article-title":"PEGylation of therapeutic proteins","volume":"5","author":"Jevsevar","year":"2010","journal-title":"Biotechnol. J."},{"issue":"18","key":"10.1016\/j.smim.2022.101633_bib125","doi-asserted-by":"crossref","first-page":"16229","DOI":"10.1074\/jbc.M110.204701","article-title":"Polyethylene glycol (PEG)-induced mouse model of choroidal neovascularization","volume":"286","author":"Lyzogubov","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.smim.2022.101633_bib126","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/rheumatology\/ket278","article-title":"PEGylated drugs in rheumatology--why develop them and do they work?","volume":"53","author":"McDonnell","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.smim.2022.101633_bib127","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ajo.2021.08.018","article-title":"Inhibition of complement factor 3 in geographic atrophy with NGM621: phase 1 dose-escalation study results","volume":"235","author":"Wykoff","year":"2021","journal-title":"Am. J. Ophthalmol."},{"issue":"9","key":"10.1016\/j.smim.2022.101633_bib128","first-page":"374","article-title":"CB2782: a complement factor C3-inactivating protease and potential long-acting treatment for Dry AMD","volume":"60","author":"Furfine","year":"2019","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.smim.2022.101633_bib129","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.str.2009.01.015","article-title":"The crystal structure of cobra venom factor, a cofactor for C3- and C5-convertase CVFBb","volume":"17","author":"Krishnan","year":"2009","journal-title":"Structure"},{"issue":"8","key":"10.1016\/j.smim.2022.101633_bib130","first-page":"183","article-title":"KNP-301, a dual inhibitor of the complement pathway and angiogenesis, effectively suppresses angiogenesis and atrophy","volume":"62","author":"Chung","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.smim.2022.101633_bib131","unstructured":"Apellis Pharmaceuticals, Apellis Pharmaceuticals Reports Third Quarter 2021. https:\/\/www.globenewswire.com\/news-release\/2021\/11\/08\/2329695\/0\/en\/Apellis-Pharmaceuticals-Reports-Third-Quarter-2021-Financial-Results.html, 2022 (accessed 12 February 2022)."},{"issue":"6","key":"10.1016\/j.smim.2022.101633_bib132","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol."},{"issue":"1","key":"10.1016\/j.smim.2022.101633_bib133","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4049\/jimmunol.174.1.491","article-title":"Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization","volume":"174","author":"Bora","year":"2005","journal-title":"J. Immunol."},{"issue":"22","key":"10.1016\/j.smim.2022.101633_bib134","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2010-08-297648","article-title":"Complement halts angiogenesis gone wild","volume":"116","author":"Kahr","year":"2010","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.smim.2022.101633_bib135","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1182\/blood-2010-01-261503","article-title":"Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis","volume":"116","author":"Langer","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.smim.2022.101633_bib136","doi-asserted-by":"crossref","first-page":"6525","DOI":"10.1167\/iovs.14-15067","article-title":"Reliability of the mouse model of choroidal neovascularization induced by laser photocoagulation","volume":"55","author":"Poor","year":"2014","journal-title":"Invest Ophthalmol. Vis. Sci."},{"issue":"17","key":"10.1016\/j.smim.2022.101633_bib137","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab","volume":"113","author":"Risitano","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.smim.2022.101633_bib138","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-017-0496-x","article-title":"Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes","volume":"10","author":"Sica","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.smim.2022.101633_bib139","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.celrep.2020.01.064","article-title":"Toll-like receptor 2 facilitates oxidative damage-induced retinal degeneration","volume":"30","author":"Mulfaul","year":"2020","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.smim.2022.101633_bib140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bjophthalmol-2016-308823","article-title":"Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options","volume":"101","author":"Tanna","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.smim.2022.101633_bib141","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-3-319-95046-4_27","article-title":"Stargardt disease","volume":"1085","author":"Tsang","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"issue":"2","key":"10.1016\/j.smim.2022.101633_bib142","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/13816810802695550","article-title":"Natural history of phenotypic changes in Stargardt macular dystrophy","volume":"30","author":"Walia","year":"2009","journal-title":"Ophthalmic Genet."},{"issue":"5","key":"10.1016\/j.smim.2022.101633_bib143","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/ceo.13947","article-title":"Stargardt disease: multimodal imaging: a review","volume":"49","author":"Heath Jeffery","year":"2021","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.smim.2022.101633_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101787","article-title":"Evidence of complement dysregulation in outer retina of Stargardt disease donor eyes","volume":"37","author":"Hu","year":"2020","journal-title":"Redox Biol."},{"issue":"15","key":"10.1016\/j.smim.2022.101633_bib145","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1073\/pnas.1620299114","article-title":"Complement modulation in the retinal pigment epithelium rescues photoreceptor degeneration in a mouse model of Stargardt disease","volume":"114","author":"Lenis","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.smim.2022.101633_bib146","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1167\/iovs.08-2868","article-title":"Complement activation by bisretinoid constituents of RPE lipofuscin","volume":"50","author":"Zhou","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.smim.2022.101633_bib147","unstructured":"Scholl H.P.T., S.H.; Kay, C.N.; et al. Stargardt disease ALK-001 phase 2 clinical trial: 12-month interim data. Invest Ophthalmol Vis Sci. 2019;60(9):1336."},{"key":"10.1016\/j.smim.2022.101633_bib148","unstructured":"Global Newswire News Room, FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation for ALK-001 (C20-D3-vitamin A) for the Treatment of Stargardt Disease. https:\/\/www.globenewswire.com\/en\/news-release\/2021\/07\/14\/2262633\/0\/en\/FDA-Grants-Alkeus-Pharmaceuticals-Breakthrough-Therapy-Designation-for-ALK-001-C20-D3-vitamin-A-for-the-Treatment-of-Stargardt-Disease.html, 2022 (accessed 28 December 2021)."},{"issue":"21","key":"10.1016\/j.smim.2022.101633_bib149","doi-asserted-by":"crossref","first-page":"18593","DOI":"10.1074\/jbc.M110.191866","article-title":"Complement system dysregulation and inflammation in the retinal pigment epithelium of a mouse model for Stargardt macular degeneration","volume":"286","author":"Radu","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"22","key":"10.1016\/j.smim.2022.101633_bib150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228468","article-title":"Cell-type-specific complement profiling in the ABCA4(-\/-) mouse model of stargardt disease","volume":"21","author":"Jabri","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"29","key":"10.1016\/j.smim.2022.101633_bib151","doi-asserted-by":"crossref","first-page":"11574","DOI":"10.1074\/jbc.RA118.002062","article-title":"A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cycle","volume":"293","author":"Racz","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"27","key":"10.1016\/j.smim.2022.101633_bib152","doi-asserted-by":"crossref","first-page":"8415","DOI":"10.1073\/pnas.1506960112","article-title":"Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization","volume":"112","author":"Charbel Issa","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.smim.2022.101633_bib153","first-page":"1569","article-title":"Complement C5 inhibition as a potential treatment for autosomal recessive Stargardt disease (STGD1): Design of a clinical trial assessing a novel treatment and primary outcome measure","volume":"59","author":"Csaky","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.smim.2022.101633_bib154","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2213-8587(19)30411-5","article-title":"Screening for diabetic retinopathy: new perspectives and challenges","volume":"8","author":"Vujosevic","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"10.1016\/j.smim.2022.101633_bib155","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/ceo.12696","article-title":"Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review","volume":"44","author":"Ting","year":"2016","journal-title":"Clin. Exp. Ophthalmol."},{"issue":"9735","key":"10.1016\/j.smim.2022.101633_bib156","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.smim.2022.101633_bib157","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/ICU.0000000000000799","article-title":"Prevention of vision-threatening complications in diabetic retinopathy: two perspectives based on results from the DRCR Retina Network Protocol W and the Regeneron-sponsored PANORAMA","volume":"32","author":"Nanegrungsunk","year":"2021","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"13","key":"10.1016\/j.smim.2022.101633_bib158","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"New Engl. J. Med."},{"issue":"3","key":"10.1016\/j.smim.2022.101633_bib159","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12031-018-1188-x","article-title":"Molecular mechanisms mediating diabetic retinal neurodegeneration: potential research avenues and therapeutic targets","volume":"66","author":"Chakravarthy","year":"2018","journal-title":"J. Mol. Neurosci."},{"issue":"4","key":"10.1016\/j.smim.2022.101633_bib160","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00125-011-2301-7","article-title":"A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3","volume":"55","author":"Hess","year":"2012","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.smim.2022.101633_bib161","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00125-014-3267-z","article-title":"Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3","volume":"57","author":"Hess","year":"2014","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.smim.2022.101633_bib162","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1021\/pr800112g","article-title":"Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy","volume":"7","author":"Gao","year":"2008","journal-title":"J. Proteome Res."},{"issue":"1","key":"10.1016\/j.smim.2022.101633_bib163","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00417-012-2024-6","article-title":"Correlation of complement fragment C5a with inflammatory cytokines in the vitreous of patients with proliferative diabetic retinopathy","volume":"251","author":"Muramatsu","year":"2013","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"11","key":"10.1016\/j.smim.2022.101633_bib164","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1167\/iovs.61.11.39","article-title":"Complement activation in the vitreous of patients with proliferative diabetic retinopathy","volume":"61","author":"Mandava","year":"2020","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.smim.2022.101633_bib165","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fimmu.2020.00154","article-title":"A systematic investigation on complement pathway activation in diabetic retinopathy","volume":"11","author":"Shahulhameed","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.smim.2022.101633_bib166","first-page":"1104","article-title":"Extensive deposits of complement C3d and C5b-9 in the choriocapillaris of eyes of patients with diabetic retinopathy","volume":"43","author":"Gerl","year":"2002","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"12","key":"10.1016\/j.smim.2022.101633_bib167","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.2337\/diabetes.51.12.3499","article-title":"Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy","volume":"51","author":"Zhang","year":"2002","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.smim.2022.101633_bib168","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2337\/diabetes.53.10.2653","article-title":"Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes","volume":"53","author":"Qin","year":"2004","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.smim.2022.101633_bib169","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2020.21899","article-title":"Glaucoma in adults-screening, diagnosis, and management: a review","volume":"325","author":"Stein","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.smim.2022.101633_bib170","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.neuron.2012.03.026","article-title":"Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner","volume":"74","author":"Schafer","year":"2012","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.smim.2022.101633_bib171","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1172\/JCI44646","article-title":"Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma","volume":"121","author":"Howell","year":"2011","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.smim.2022.101633_bib172","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00347-014-3100-6","article-title":"Complement activation after induction of ocular hypertension in an animal model","volume":"112","author":"Becker","year":"2015","journal-title":"Ophthalmologe"},{"issue":"15\u201316","key":"10.1016\/j.smim.2022.101633_bib173","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.molimm.2011.07.012","article-title":"Complement mediated apoptosis leads to the loss of retinal ganglion cells in animal model of glaucoma","volume":"48","author":"Jha","year":"2011","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.smim.2022.101633_bib174","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13024-016-0091-6","article-title":"Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma","volume":"11","author":"Williams","year":"2016","journal-title":"Mol. Neurodegener."},{"issue":"10","key":"10.1016\/j.smim.2022.101633_bib175","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.ymthe.2018.08.017","article-title":"Complement C3-targeted gene therapy restricts onset and progression of neurodegeneration in chronic mouse glaucoma","volume":"26","author":"Bosco","year":"2018","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.smim.2022.101633_bib176","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00401-021-02366-4","article-title":"Complement component 3 from astrocytes mediates retinal ganglion cell loss during neuroinflammation","volume":"142","author":"Gharagozloo","year":"2021","journal-title":"Acta Neuropathol."},{"issue":"19","key":"10.1016\/j.smim.2022.101633_bib177","doi-asserted-by":"crossref","first-page":"E3839","DOI":"10.1073\/pnas.1608769114","article-title":"Early immune responses are independent of RGC dysfunction in glaucoma with complement component C3 being protective","volume":"114","author":"Harder","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.smim.2022.101633_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108077","article-title":"The aqueous humor proteome of primary open angle glaucoma: an extensive review","volume":"197","author":"Hubens","year":"2020","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.smim.2022.101633_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2021.108460","article-title":"Increased ratios of complement factors C3a to C3 in aqueous humor and serum mark glaucoma progression","volume":"204","author":"Hubens","year":"2021","journal-title":"Exp. Eye Res"},{"issue":"1","key":"10.1016\/j.smim.2022.101633_bib180","first-page":"40","article-title":"Retinal vein occlusion review. Asia Pac","volume":"7","author":"Ip","year":"2018","journal-title":"Asia Pac. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.smim.2022.101633_bib181","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ajpath.2019.01.009","article-title":"Complement factor H mutation W1206R causes retinal thrombosis and ischemic retinopathy in mice","volume":"189","author":"Song","year":"2019","journal-title":"Am. J. Pathol."},{"issue":"14","key":"10.1016\/j.smim.2022.101633_bib182","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/iovs.61.14.6","article-title":"Aqueous fibronectin correlates with severity of macular edema and visual acuity in patients with branch retinal vein occlusion: a proteome study","volume":"61","author":"Cehofski","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"6","key":"10.1016\/j.smim.2022.101633_bib183","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158001","article-title":"Proteomic analysis of vitreous humor in retinal vein occlusion","volume":"11","author":"Reich","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.smim.2022.101633_bib184","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3129\/i10-060","article-title":"Visual improvement in established central retinal vein occlusion with long-standing macular edema following systemic eculizumab treatment","volume":"45","author":"Lockington","year":"2010","journal-title":"Can. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.smim.2022.101633_bib185","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.immuni.2017.01.006","article-title":"Complement factor H inhibits CD47-mediated resolution of inflammation","volume":"46","author":"Calippe","year":"2017","journal-title":"Immunity"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532322000501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532322000501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:21:21Z","timestamp":1760916081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532322000501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":185,"alternative-id":["S1044532322000501"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2022.101633","relation":{},"ISSN":["1044-5323"],"issn-type":[{"type":"print","value":"1044-5323"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging opportunities for C3 inhibition in the eye","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2022.101633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101633"}}